vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and ROYAL GOLD INC (RGLD). Click either name above to swap in a different company.

ROYAL GOLD INC is the larger business by last-quarter revenue ($375.3M vs $267.3M, roughly 1.4× Ascendis Pharma A/S). On growth, ROYAL GOLD INC posted the faster year-over-year revenue change (85.3% vs 42.3%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 58.8%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

Royal Gold Inc. is a leading precious metals streaming and royalty firm that acquires and manages a diversified portfolio of streaming interests, royalties, and equity interests tied to mining projects. Its assets cover gold, silver, and copper production across North America, South America, Africa, and Australia, operating with a low-risk model that avoids direct mining operations.

ASND vs RGLD — Head-to-Head

Bigger by revenue
RGLD
RGLD
1.4× larger
RGLD
$375.3M
$267.3M
ASND
Growing faster (revenue YoY)
RGLD
RGLD
+43.0% gap
RGLD
85.3%
42.3%
ASND
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
58.8%
RGLD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASND
ASND
RGLD
RGLD
Revenue
$267.3M
$375.3M
Net Profit
$93.6M
Gross Margin
90.5%
64.6%
Operating Margin
56.2%
Net Margin
24.9%
Revenue YoY
42.3%
85.3%
Net Profit YoY
-12.8%
EPS (diluted)
$1.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
RGLD
RGLD
Q4 25
$267.3M
$375.3M
Q3 25
$230.7M
$252.1M
Q2 25
$170.7M
$209.6M
Q1 25
$109.0M
$193.4M
Q4 24
$187.8M
$202.6M
Q3 24
$62.5M
$193.8M
Q2 24
$38.9M
$174.1M
Q1 24
$103.6M
$148.9M
Net Profit
ASND
ASND
RGLD
RGLD
Q4 25
$93.6M
Q3 25
$-65.9M
$126.8M
Q2 25
$-42.0M
$132.3M
Q1 25
$-102.2M
$113.5M
Q4 24
$107.4M
Q3 24
$-107.1M
$96.2M
Q2 24
$-118.1M
$81.2M
Q1 24
$-141.5M
$47.2M
Gross Margin
ASND
ASND
RGLD
RGLD
Q4 25
90.5%
64.6%
Q3 25
89.5%
73.6%
Q2 25
80.1%
72.6%
Q1 25
82.6%
69.4%
Q4 24
91.9%
70.3%
Q3 24
80.6%
66.6%
Q2 24
68.2%
64.7%
Q1 24
92.1%
58.4%
Operating Margin
ASND
ASND
RGLD
RGLD
Q4 25
56.2%
Q3 25
5.1%
64.4%
Q2 25
-33.5%
67.7%
Q1 25
-103.2%
63.6%
Q4 24
65.9%
Q3 24
-167.3%
61.3%
Q2 24
-370.2%
58.6%
Q1 24
-51.2%
50.7%
Net Margin
ASND
ASND
RGLD
RGLD
Q4 25
24.9%
Q3 25
-28.5%
50.3%
Q2 25
-24.6%
63.1%
Q1 25
-93.7%
58.7%
Q4 24
53.0%
Q3 24
-171.5%
49.7%
Q2 24
-303.9%
46.6%
Q1 24
-136.6%
31.7%
EPS (diluted)
ASND
ASND
RGLD
RGLD
Q4 25
$1.04
Q3 25
$1.92
Q2 25
$2.01
Q1 25
$1.72
Q4 24
$1.63
Q3 24
$1.46
Q2 24
$1.23
Q1 24
$0.72

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
RGLD
RGLD
Cash + ST InvestmentsLiquidity on hand
$665.3M
$233.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-175.8M
$7.2B
Total Assets
$1.4B
$9.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
RGLD
RGLD
Q4 25
$665.3M
$233.7M
Q3 25
$582.2M
$172.8M
Q2 25
$533.6M
$248.2M
Q1 25
$559.4M
$240.8M
Q4 24
$604.3M
$195.5M
Q3 24
$675.6M
$127.9M
Q2 24
$279.4M
$74.2M
Q1 24
$345.9M
$137.9M
Total Debt
ASND
ASND
RGLD
RGLD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$0
Q2 24
$50.0M
Q1 24
Stockholders' Equity
ASND
ASND
RGLD
RGLD
Q4 25
$-175.8M
$7.2B
Q3 25
$-188.0M
$3.4B
Q2 25
$-202.6M
$3.3B
Q1 25
$-205.0M
$3.2B
Q4 24
$-114.2M
$3.1B
Q3 24
$-105.1M
$3.0B
Q2 24
$-346.8M
$3.0B
Q1 24
$-257.2M
$2.9B
Total Assets
ASND
ASND
RGLD
RGLD
Q4 25
$1.4B
$9.5B
Q3 25
$1.2B
$4.5B
Q2 25
$1.2B
$3.6B
Q1 25
$1.1B
$3.5B
Q4 24
$1.3B
$3.4B
Q3 24
$1.2B
$3.3B
Q2 24
$819.0M
$3.3B
Q1 24
$866.7M
$3.3B
Debt / Equity
ASND
ASND
RGLD
RGLD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.00×
Q2 24
0.02×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
RGLD
RGLD
Operating Cash FlowLast quarter
$58.2M
$241.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
2.58×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
RGLD
RGLD
Q4 25
$58.2M
$241.7M
Q3 25
$174.0M
Q2 25
$152.8M
Q1 25
$-15.5M
$136.4M
Q4 24
$-330.7M
$141.1M
Q3 24
$136.7M
Q2 24
$113.5M
Q1 24
$-109.7M
$138.3M
Cash Conversion
ASND
ASND
RGLD
RGLD
Q4 25
2.58×
Q3 25
1.37×
Q2 25
1.15×
Q1 25
1.20×
Q4 24
1.31×
Q3 24
1.42×
Q2 24
1.40×
Q1 24
2.93×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASND
ASND

Segment breakdown not available.

RGLD
RGLD

Gold$216.9M58%
Pueblo Viejo$47.3M13%
Andacollo$32.6M9%
Silver$32.1M9%
Other$27.2M7%
Copper$13.7M4%
Cortez Legacy Zone$5.4M1%

Related Comparisons